第67回日本腎臓学会学術総会

セッション情報

一般演題口演

一般演題口演 CKD English

2024年6月30日(日) 13:40 〜 14:40 第4会場 (ノース 3階 G312+G313)

Chair:Shinji Tanaka(Division of Nephrology and Endocrinology, The University of Tokyo Hospital)

Arihiro Kiyosue1, Hiddo Jan L. Heerspink2, David C. Wheeler3, Tomoko Ishizu4, Min Lin5, Emma Wijkmark6, Glenn F. Carlson5, Anne-Kristina Mercier6, Magnus Astrand6, Peter J. Greasley6, Philip D. Ambery6 (1.Tokyo-EKI Center-building Clinic, Tokyo, Japan, 2.Universiteit Groningen, Groningen, Netherlands, 3.University College London, London, United Kingdom, 4.AstraZeneca, Tokyo, Japan, 5.AstraZeneca, Gaithersburg, USA, 6.AstraZeneca, Gothenburg, Sweden)

Terumasa Hayashi1, Silvio E. Inzucchi2, Gerasimos Filippatos3, Stefan D. Anker4, Christoph Wanner5, Tariq Shafi6, Navdeep Tangri7, Bertram Pitt8, Robert Weingold2, Meike Brinker9, Charlie Scott9, Luke Roberts9, Peter Rossing10 (1.Osaka General Medical Center, Japan, 2.Yale School of Medicine, USA, 3.National and Kapodistrian University of Athens, Greece, 4.Charité Universitätsmedizin, Germany, 5.Universitätsklinik Würzburg, Germany, 6.Houston Methodist Academic Institute, USA, 7.Max Rady College of Medicine, Canada, 8.University of Michigan School of Medicine, USA, 9.Bayer, 10.Steno Diabetes Center Copenhagen, Denmark)

Hidetoshi Kanai1, Robert J. Mentz2, Stefan D. Anker3, Bertram Pitt4, Peter Rossing5, Luis M. Ruilope6, Martin Gebel7, Peter Kolkhof7, Robert Lawatscheck7, Katja Rohwedder7, George L. Bakris8 (1.Kokura Memorial Hospital, Japan, 2.Duke University School of Medicine, USA, 3.Charité Universitätsmedizin Berlin, Germany, 4.University of Michigan, USA, 5.Steno Diabetes Center-Copenhagen, Denmark, 6.Institute of Research imas12, Spain, 7.Bayer AG, Germany, 8.University of Chicago Medicine, USA)

Yoshitsugu Obi1, Xiaoqian Zhu1, Maria Clarissa Tio1, Timothy, E Yen1, Michael Hall1, Neville, R Dossabhoy1, Tariq Shafi2 (1.Department of Medicine, University of Mississippi Medical Center, Jackson, MS, USA, 2.Division of Kidney Diseases, Hypertension, & Transplantation, Houston Methodist Hospital, Huston, TX, USA)

Naoki Kashihara1, Hiroshi Kanegae2, Suguru Okami3, Kanae Yoshikawa-Ryan3, Nikolaus G Oberprieler4, Manel Pladevall-Vila5, J Bradley Layton6, Satoshi Yamashita3, Catherine Johannes7, Alredo E. Farjat8, Csaba P. Kovesdy9, David Vizcaya4, Yuichiro Yano10 (1.Department of Nephrology and Hypertension, Kawasaki Medical School, Kurashiki, Japan, 2.Genki Plaza Medical Center for Health Care, Office of Research and Analysis, Tokyo, Japan, 3.Bayer Yakuhin Ltd., Medical Affairs & Pharmacovigilance, Osaka, Japan, 4.Integrated Evidence Generation & Business Innovation, Bayer AG, 13342 Berlin, Germany, 5.RTI Health Solutions, Pharmacoepidemiology and risk management, Barcelona, Spain, 6.RTI Health Solutions, Pharmacoepidemiology and risk management, Research Triangle Park NC, USA, 7.RTI Health Solutions, Pharmacoepidemiology and risk management, Waltham MA, USA, 8.Bayer PLC, Statistics & Data Insights, Reading, United Kingdom, 9.University of Tennessee, Health Science Center, Department of Medicine, Memphis TN, USA, 10.Shiga University of Medical Science, Department of Advanced Epidemiology NCD Epidemiology Research Center, Otsu, Japan)